Description
Latin name
Triducard
Release form
Film-modified release tablets.
Packing
60 tablets.
Pharmacological action
Pharmacotherapeutic group: antihypoxic drug.
ATX code: [ ¡01 15]
Pharmacological properties of
Pharmacodynamics:
Trimetazidine has an antianginal, antihypoxic effect. Directly affecting cardiomyocytes and brain neurons, it optimizes their metabolism and function. The cytoprotective effect is due to increased energy potential, activation of oxidative decarboxylation and rationalization of oxygen consumption (increased aerobic glycolysis and blockade of fatty acid oxidation). It supports myocardial contractility, prevents a decrease in the intracellular content of ATP and phosphocreatinin. In conditions of acidosis, it normalizes the functioning of ion channels, prevents the accumulation of calcium and sodium in cardiomyocytes, normalizes the intracellular content of potassium ions. Reduces intracellular acidosis and phosphate concentrations due to myocardial ischemia and reperfusion. It prevents the damaging effect of free radicals, preserves the integrity of cell membranes, prevents the activation of neutrophils in the ischemic zone, increases the duration of the electric potential, reduces the yield of creatine phosphokinase from the cells and the severity of ischemic damage to the myocardium. With angina pectoris, it reduces the frequency of seizures (nitrate consumption decreases), after 2 weeks of treatment, exercise tolerance increases, blood pressure drops decrease. Improves hearing and results of vestibular tests in patients, reduces dizziness and tinnitus. With vascular pathology, the eye restores the functional activity of the retina.
Pharmacokinetics:
After taking the drug inside, trimetazidine is rapidly and almost completely absorbed from the gastrointestinal tract. Bioavailability is 90%. The time to reach maximum plasma concentration is 2 hours. The maximum concentration after a single dose of 35 mg of trimetazidine is about 55 ng / ml. It easily passes through histohematological barriers. The half-life (T1 / 2) is 4.5-5 hours. Communication with plasma proteins – 16%. It is excreted from the body by the kidneys (about 60% – unchanged).
Contraindications
Hypersensitivity to any component of the drug Triducard
Renal failure (creatinine clearance below 15 ml / min)
Severe hepatic dysfunction
Pregnancy
Breastfeeding and unclean age 18 years of safety.
Use during pregnancy and lactation
The drug Triducard is contraindicated for use during pregnancy and during breastfeeding.
Composition
one film-coated modified release tablet contains the active substance trimetazidine dihydrochloride 35 mg. Excipients: hypromellose (metocel K 4M Premium EP) – 54 mg microcrystalline cellulose – 118 mg silicon colloidal dioxide (aerosil) – 1 mg magnesium stearate – 1 mg
Shell composition: Hydroxypropyl methylcellulose (hypromellose) – 4.628 mg talc – 0.357 mg titanium -1.002 mg macrogol (polyethylene oxide 4000) – 1.002 mg dye azorubine (acid red 2C for pharmaceutical purposes) – 0.011 mg.
Description: tablets film-coated pink, round, biconvex. 30 tablets of 35 mg.
Dosage and Administration
Inside, with food. The recommended dosage regimen is 2 tablets (70 mg) per day, in 2 divided doses. The course of treatment is recommended by a doctor.
Side effects
Allergic reactions: itchy skin.
From the digestive system: rarely – gastralgia, nausea, vomiting.
From the cardiovascular system: rarely – headache, sensation of a strong heartbeat.
Overdose
No overdose has been reported at this time.
Storage Conditions
The product should be stored in a dry, dark place out of the reach of children at a temperature not exceeding 25 ° C.
Shelf life
3 years.
Deystvuyushtee substance
trimetazidine
Terms and conditions
prescription
Dosage form
prolong tablets.
Possible product names
TRIDUCARD 0,035 N60 TABLE WITH MODIF P / O
Triducard 35mg Tab. with modif. exp. p / pl / rev X60
TRIDUCARD 35MG. No. 60 TAB. P / O MODIF. HIGH.
Triducard MV 35mg No. 60
Triducard MV 35 mg tablets, 60 pcs.
North Star, Russia
